| |
著者: Patrick G P Charles, Peter B Ward, Paul D R Johnson, Benjamin P Howden, M Lindsay Grayson
雑誌名: Clin Infect Dis. 2004 Feb 1;38(3):448-51. doi: 10.1086/381093. Epub 2004 Jan 12.
Abstract/Text
We assessed all episodes of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12-month period (n=53) and compared those due to heterogeneous vancomycin-intermediate S. aureus (hVISA; n = 5, 9.4%) with those due to vancomycin-susceptible MRSA (n=48). Patients with hVISA bacteremia were more likely to have high bacterial load infections (P=.001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P<.001), and initially low serum vancomycin levels (P=.006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment.
PMID 14727222 Clin Infect Dis. 2004 Feb 1;38(3):448-51. doi: 10.1086/381093. Epub 2004 Jan 12.
|
